Skip to main content

Merck & Co., Inc. (MRK)

NYSE: MRK · Delayed Price · USD
74.06
+1.01 (1.38%)
Pre-market:Sep 24, 2021 6:54 AM EDT
73.05
1.01 (1.40%)
At close: Sep 23, 4:00 PM
Market Cap182.18B
Revenue (ttm)48.55B
Net Income (ttm)5.57B
Shares Out2.53B
EPS (ttm)2.20
PE Ratio33.27
Forward PE10.65
Dividend$2.52 (3.45%)
Ex-Dividend DateSep 14, 2021
Volume10,968,784
Open72.66
Previous Close72.04
Day's Range72.57 - 74.04
52-Week Range15.05 - 83.38
Beta0.42
AnalystsBuy
Price Target92.42 (+26.5%)
Est. Earnings DateOct 28, 2021

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as we...

IndustryPharmaceuticals
Founded2000
CEOKenneth Frazier
Employees73,000
Stock ExchangeNYSE
Ticker SymbolMRK
Full Company Profile

Financial Performance

In 2020, Merck's revenue was $47.99 billion, an increase of 2.46% compared to the previous year's $46.84 billion. Earnings were $7.07 billion, a decrease of -28.20%.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for Merck stock is "Buy." The 12-month stock price forecast is 92.42, which is an increase of 26.52% from the latest price.

Price Target
$92.42
(26.52% upside)
Analyst Consensus: Buy

News

AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients

AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza pl...

Other symbols:AZN
19 minutes ago - Benzinga

LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial

28 minutes ago - Business Wire

Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255

Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

Other symbols:NKTRPFE
1 day ago - Zacks Investment Research

Should You Buy Merck Stock At $72?

The stock price of ​Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, and it currently trades at levels of arou...

1 day ago - Forbes

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study

Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in c...

Other symbols:NKTRPFE
2 days ago - Benzinga

These 3 Dow Stocks Are Set to Soar in 2021's Second Half and Beyond

Scoop up these underestimated blue chips while they're not getting much love from the market.

Other symbols:DISHD
2 days ago - The Motley Fool

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $71.93 in the latest trading session, marking a +0.35% move from the prior day.

3 days ago - Zacks Investment Research

Big Pharma Stocks Hit Hard by Drug Price Proposals

Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...

Other symbols:BMYJNJLLYPFE
3 days ago - GuruFocus

Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

3 days ago - Zacks Investment Research

Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data

Merck & Co Inc (NYSE: MRK) announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative...

3 days ago - Benzinga

Could Pfizer and Merck Be Big Winners With COVID Pills?

The short answer: Yes.

Other symbols:PFE
4 days ago - The Motley Fool

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Tr...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemo as 1L Treatment for Patients With Metastatic TNBC Whose Tumors Expressed PD L1 (CPS ≥10)

4 days ago - Business Wire

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Demonstrated Superior Recurrence-Free Survival in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo

5 days ago - Business Wire

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Ve...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus Chemo ± Bev Reduced Risk of Death by 33% Vs Chemo ± Bev as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

5 days ago - Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Pa...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination with Chemo for Certain Patients with Metastatic TNBC

6 days ago - Business Wire

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Other symbols:HOOK
1 week ago - Zacks Investment Research

What's Next For Merck Stock After A 5% Fall In A Week?

The stock price of ​Merck reached its all-time high of around $82 in Sep 2020. It has since hovered in the range of $70-80 for the better part of the last year, before a recent sell-off in pharmaceutica...

1 week ago - Forbes

Option Trade: This Put Backspread In Merck Stock Offers Unlimited Upside Potential

For today's trade, we're looking at a put backspread in Merck. This trade profits if the stock stays flat or produces a big drop before expiration and the maximum upside potential is unlimited up to the...

1 week ago - Investors Business Daily

Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial

Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (...

Other symbols:HOOK
1 week ago - Benzinga

3 No-Brainer Warren Buffett Stocks to Buy Right Now

Not every name Berkshire Hathaway holds is right for all investors, but any of these three picks would be at home in almost any investor's portfolio.

Other symbols:MAVZ
1 week ago - The Motley Fool

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed at $73.18 in the latest trading session, marking a -0.37% move from the prior day.

1 week ago - Zacks Investment Research

A Look at R&D Spending in Pharma

In GAAP accounting, fixed assets are usually capitalized on a company's balance sheet and subsequently amortized over their expected useful life.

Other symbols:AZNGSKJNJNVSPFE
1 week ago - GuruFocus

3 Dow Jones Stocks to Buy Hand Over Fist Right Now

These large companies still have what it takes to serve up big wins.

Other symbols:AAPLCAT
1 week ago - The Motley Fool

How Keytruda's Latest Approval in China Boosts Merck

Keytruda received its second regulatory approval in China for the treatment of esophageal cancer.

1 week ago - The Motley Fool

3 Smartest Big Pharma Stocks to Buy in September

You can go big this month with these three pharmaceutical stocks.

Other symbols:PFETEVA
1 week ago - The Motley Fool